Eikon Therapeutics, EIK1001, TeLuRide-005, TeLuRide-008, NSCLC, Non-Small Cell Lung Cancer, Stage 4 Lung Cancer, Phase 2 Clinical Trial, Phase 2/3 Trial, ESMO 2026, TLR7/8 Agonist,

MILLBRAE, Calif. — October 26, 2026 Eikon Therapeutics (Nasdaq: EIKN) announced updated clinical data from the open-label TeLuRide-005 trial,...